Experience with Selexipag to Treat Pulmonary Arterial Hypertension

Aim To present an own experience in using a medication selexipag in patients with pulmonary arterial hypertension (PAH) included into the V. A. Almazov National Medical Research Center registry and participating in the GRIPHON and GRIPHON OL clinical studies.
Material and methods 26 patients with PAH were included into this study since 2010: 20 patients with idiopathic PAH, 4 patients with PAH associated with systemic scleroderma, and 2 patients with corrected congenital heart defects. At the time of randomization, 19 patients had been receiving therapy with phosphodiesterase type 5 inhibitors for at least one month. Among the patients treated with selexipag (n=14), 4 patients reached a high individual maintenance dose (1200–1600 µg b.i.d.), 4 patients reached a medium dose (600–1000 µg b.i.d.), and 6 patients reached a low dose (200–400 µg b.i.d.).
Results The selexipag therapy exerted a positive effect on secondary endpoints, specifically, on changes in the functional class of pulmonary hypertension, serum concentration of NT-proBNP, and physical working capacity of patients. Adverse events associated with the selexipag treatment, which resulted in termination of study participation, were observed in one patient.
Conclusion To achieve the main goal of drug therapy, low risk of death with selexipag it is critical to observe the titration schedule and to aim at reaching the highest individual maintenance dose.

1. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67–119. DOI: 10.1093/eurheartj/ehv317

2. Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(9):834–44. DOI: 10.1056/NEJMoa1413687

3. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(9):809–18. DOI: 10.1056/NEJMoa1213917

4. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(26):2522–33. DOI: 10.1056/NEJMoa1503184

5. Humbert M, Ghofrani H-A. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax. 2016;71(1):73–83. DOI: 10.1136/thoraxjnl-2015-207170

6. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respiratory Medicine. 2010;104(1):9–21. DOI: 10.1016/j.rmed.2009.07.015

7. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging. 2015;16(3):233–71. DOI: 10.1093/ehjci/jev014

8. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal. 2017;50(2):1602493. DOI: 10.1183/13993003.02493-2016

9. Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani H et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure. 2019;21(3):352–9. DOI: 10.1002/ejhf.1375

10. Satoh M, Aso K, Nakayama T, Saji T. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. Endocrine Journal. 2017;64(12):1173–80. DOI: 10.1507/endocrj.EJ17-0155

11. Baker WL, Darsaklis K, Singhvi A, Salerno EL. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension. Annals of Pharmacotherapy. 2017;51(6):488–95. DOI: 10.1177/1060028017697424

12. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2012;40(4):874–80. DOI: 10.1183/09031936.00137511

13. Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M et al. Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801908. DOI: 10.1183/13993003.01908-2018

14. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani H-A et al. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs. 2018;18(1):37–47. DOI: 10.1007/s40256-017-0262-z

15. Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. European Heart Journal. 2018;39(47):4175–81. DOI: 10.1093/eurheartj/ehx257

16. Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA et al. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. The Journal of Heart and Lung Transplantation. 2019;38(1):43–50. DOI: 10.1016/j.healun.2018.09.003

17. Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology. 2016;32(12):1520–30. DOI: 10.1016/j.cjca.2016.03.004

18. Hoeper MM, Apitz C, Grünig E, Halank M, Ewert R, Kaemmerer H et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology. 2018;272S:37–45. DOI: 10.1016/j.ijcard.2018.08.082

19. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O et al. Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018

20. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal. 2017;50(2):1700740. DOI: 10.1183/13993003.00740-2017